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SUITABILITY AND REPEATABILITY OF A
PHOTOSTRESS RECOVERY TEST DEVICE,
THE MACULAR DEGENERATION
DETECTOR (MDD-2), FOR DIABETES AND
DIABETIC RETINOPATHY ASSESSMENT
JAMES LOUGHMAN, PHD,*† MATTHEW RATZLAFF, BSC,‡ BRITTANY FOERG, BSC,*
PAUL CONNELL, MD‡
Background: Diabetic retinopathy can result in impaired photostress recovery time
despite normal visual acuity and fundoscopic appearance. The Macular Degeneration
Detector (MDD-2) is a novel ﬂash photostress recovery time device. In this study, we
examine the repeatability of the MDD-2 in normal and diabetic subjects.
Methods: One hundred and ninety one (90 women, 101 men) subjects were recruited
and divided into 1 of the 3 study groups (normal controls, n = 40; diabetes no retinopathy,
n = 98; nonproliferative diabetic retinopathy, n = 53). Photostress recovery time was measured three times in the study eye using the MDD-2, each measurement separated by
a 5-minute interval.
Results: Repeated measures analysis of variance revealed no statistically signiﬁcant
learning or fatigue effects on intrameasurement repeatability for any group. Photostress
recovery time measures were broadly similar and typically not statistically signiﬁcantly
different between study groups. The coefﬁcient of repeatability reached clinically acceptable levels once the initial photostress recovery time measure, which demonstrated
increased variability and latency compared with all subsequent measures, was excluded.
Conclusion: The MDD-2 seems to provide repeatable photostress recovery time
measurements among naive diabetic subjects. The device does not, however, seem
capable of differentiating normal and nonproliferative diabetic eyes, and would not be
suitable for inclusion in diabetic retinopathy screening protocol.
RETINA 0:1–8, 2013
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habits are creating an emerging disease proﬁle that
includes diabetes and DR.6–8
The development of ocular complications in diabetes is related to disease control and longevity. After
20 years, more than 75% of patients will have some
form of DR.9 It has been suggested, however, that
visual loss associated with the development of DR
could be reduced for the majority of patients with
proper and vigilant monitoring of diabetic eyes, and
prompt treatment initiation where required.10 Earlier
detection and more effective management can delay
disease progression, prevent debilitating sight loss,
and thereby reduce future dependency on health care
services. This is particularly important in light of the
likely increase in visual impairment and blindness set
to accompany increasing diabetes prevalence,11 and

he global population is aging and life expectancy
is increasing. Current lifestyle habits are leading to
an epidemic in obesity and cardiovascular disease,
including diabetes.1–5 Even in developing countries,
where diabetic retinopathy (DR) has not been a historically signiﬁcant cause of blindness, the demographic
change and westernization of dietary and lifestyle
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the substantial personal and societal (including economic) costs associated with such avoidable visual
impairment.12 The possibilities for retarding disease
progression including recent advances in pharmacologic management of diabetic maculopathy, best
applied at the earliest stages of the development of
abnormal pathology, further increase the priority that
should be afforded to effective disease monitoring.13–15
Diabetic maculopathy is the most common cause of
visual loss in diabetic patients. Visual acuity represents
the most widely used test of visual, and in particular
macular, function. Visual acuity alone, however, is an
inadequate biomarker of visual function in macular
disease, and can be relatively insensitive to the impact
of functional deterioration in the early stages of diabetic
macular disease.16,17 Alternative tests of visual function
have, however, proved capable of isolating macular
functional loss in cases where visual acuity remains
normal, including contrast sensitivity,17–20 color
vision,21,22 and chromatic sensitivity.23,24 In particular,
photostress recovery has also been shown to be
adversely affected by diabetic macular disease.25–27
Photostress recovery time (PSRT) describes the time
required to regain normal visual function following
exposure to intense light that bleaches the visual
pigments and saturates the response of the macular
photoreceptors, and thereby effects a transient loss of
vision.28 Normal recovery is dependent on the underlying retinal photoreceptor and pigment epithelium
function.29 The Macular Degeneration Detector
(MDD-2) is a novel ﬂash photostress recovery device.
This device has previously been shown to be capable
of detecting functional vision loss in age-related macular degeneration and diabetic maculopathy.25 It has
also been shown to provide reproducible measurements in a young healthy population.30 No previous
study, however, has explored the learning effect and
repeatability of test measures among a diabetic population without maculopathy. In this study, we examine
the repeatability of the MDD-2 in such a population in
comparison to an age-matched normal population, as
a means to determine 1) whether the device can provide clinically acceptable repeat test measures, and 2)
whether diabetes, or nonproliferative DR in the
absence of maculopathy, has an effect on PSRT compared with normal controls (NCs).

Materials and Methods
One hundred and ninety one subjects (90 women,
101 men) participated in this study which received
local Research Ethics committee approval. Informed
consent was obtained from each volunteer, and the

experimental procedures adhered to the tenets of the
Declaration of Helsinki.
Diabetic subjects were recruited from eligible retinal
clinic attendees at the Mater Misericordiae hospital,
Dublin, Ireland. Normal (nondiabetic) subjects were
recruited at the National Optometry Centre at Dublin
Institute of Technology, Dublin, Ireland. Subjects
were assigned, on the basis of their diabetic and ocular
health status, to 1 of the 3 study groups: diabetes no
retinopathy, n = 98 (48 women, 50 men); nonProliferative DR, n = 53 (20 women, 33 men); NC, n = 40 (22
women; 18 men). The following diabetes relevant
information was recorded for each diabetic participant:
diabetes duration (years), diabetes type, diabetes medication, and retinopathy grade (graded according to
modiﬁed two-ﬁeld Early Treatment Diabetic Retinopathy Study protocol; grade range, R0 M0–R2 M0).31
Generic inclusion criteria were as follows: subjects
were to be over 18 years of age, and have LogMAR
visual acuity better than 0.2 (6/9) in the study eye; and
subjects were required to be able to identify the
baseline numeric stimulus presented by the device
without their refractive correction. For normal subjects, exclusion criteria included any sign of retinal or
ocular abnormality and the presence of Type 1 or Type
2 diabetes. Subjects with diabetes were excluded if
they exhibited signs of ocular comorbidity (e.g., agerelated macular degeneration, glaucoma, cataract), had
previously undergone any form of treatment for DR or
diabetic maculopathy, or if they exhibited any signs of
proliferative retinopathy or maculopathy.
A computer generated LogMAR test chart (Thomson 2000 Pro; Thomson Software Solutions, Hatﬁeld,
United Kingdom) was used to determine LogMAR
acuity. Iris color was recorded using an iris color
classiﬁcation scheme, with iris color matched to
standard color photographs and classiﬁed into one of
the ﬁve color categories (gray, blue, green, light
brown, brown) as described by Seddon et al.32 Slitlamp indirect ophthalmoscopy and retinal photography
(Zeiss Visucam Pro NM [Carl Zeiss Meditec,
Germany], 45° ﬁeld, 1 disk and 1 macula centered
photograph) was conducted for all subjects.
Photostress recovery time was measured using the
MDD-2 Macular Degeneration Detection device
(Icandy Digital, LLC, FL). The MDD-2 is a relatively
simple device, comprising a spectrally broadband
xenon ﬂash light source (with good short-term
[1%] and long-term [3%] output stability), a UV
and IR ﬁlter, and focusing (+8 diopters) lens. The test
involves accurate identiﬁcation (postﬂash photostress)
of a large (0.41 radian/23.49° angular subtense) randomly generated number between 0 and 9. The target
is viewed through a 12-mm central aperture in the
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ﬂash tube. The 200-msecond duration ﬂash is generated by a xenon ﬂash source, mounted inside the ﬂash
tube within the subject’s ﬁeld of view, extending
across an angular subtense of 38° of visual angle.
All subjects recruited into the study were naive to
the MDD-2 test. The nature of the test and stimuli
were described in detail to each subject, and the
subject was requested to conﬁrm their understanding
of the task. The ﬂash tube was positioned against the
test eye, and the subject was required to correctly
identify a baseline, prephotostress, numeric stimulus
without their refractive correction. Subjects were
instructed to ﬁxate centrally at the position of the
prebleach stimulus, and to avoid blinking at the onset
of the photostress ﬂash. When ready to commence the
test proper, the subject pressed a button on the device
that initiated three concurrent processes: the arc ﬂash
photostress, the photostress recovery timer, and a new
random number, which was displayed continuously
until a recognition response was given. The subject
was required to verbally identify the new number, and
simultaneously, to press the same button on the device
to cease the test at the instant when vision recovered
sufﬁciently to allow number recognition.
The study eye was selected as the eye with better
visual acuity, or in cases of equal acuity, the right eye
was selected as standard. The PSRT measurement was
conducted in the study eye, and repeated on two
further occasions, each separated by a 5-minute
interval, providing a set of 3 PSRT measures (PSRT
1, PSRT 2, and PSRT 3). Incorrect identiﬁcation of the
test stimulus, at baseline, resulted in exclusion from
the study. A single incorrect response during the test
phase was permitted (result discarded and test repeated
after a 5-minute interval), but a second incorrect
response resulted in exclusion from the study. Where
both eyes met the study inclusion criteria, PSRT
measures were also recorded for the fellow eye to
facilitate intereye comparison.
The statistical software package SPSS (version 20;
SPSS, Inc, Chicago, IL) was used for analysis. Oneway analysis of variance was used to test for differences in study parameters between the groups.
Repeated measures analysis of variance was used to
test for learning or fatigue effects that might confound
analysis of repeat measures in the study eye. Paired
samples t-tests were used to test for PSRT differences
between eyes. Pearson correlation coefﬁcients were
calculated to investigate the relationship between
sequential measurements, and between eyes. Bland–
Altman analysis and plots, and the limits of agreement,
were used to quantify the agreement between repeat
measures of PSRT.33 Intrameasurement repeatability is
expressed as a coefﬁcient of repeatability, which was
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calculated as the standard deviation of the mean difference between measurements, and multiplied by
1.96. A 5% signiﬁcance level was used throughout
the analysis.
Results
All participants successfully identiﬁed the baseline
pretest stimulus and advanced to the test phase of the
investigation. Demographic and health status information, stratiﬁed according to study group, is presented in
Table 1.

T1

Intergroup Analysis
The mean (±standard deviation) visual acuity of
each study group was: diabetes no retinopathy = logMAR −0.04 (±0.10); DR = logMAR −0.06 (±0.12);
NC = logMAR −0.06 (±0.10). One-way analysis of
variance revealed no statistically signiﬁcant differences in sex (P = 0.23), iris color (P = 0.34), or visual
acuity (P = 0.70) between the 3 study groups. Statistically signiﬁcant differences were observed between
groups, however, for age (P , 0.01) and diabetes
duration (P , 0.01).
Mean (±standard deviation) PSRT for each of the
3 measurements in the study eye is presented in Table 2,
and demonstrates a trend toward improved PSRT with
each sequential measurement in the study eye, with the
most substantial improvement in PSRT immediately
after the baseline test, between PSRT 1 and 2.
A statistically signiﬁcant difference between groups
was observed for PSRT 2 (P = 0.01), but not for PSRT
1 (P = 0.13) or PSRT 3 (P = 0.09) measures. Posthoc
analysis (Scheffe test) isolated the variance in the
PSRT 2 measure to the nonproliferative DR group,
whose PSRT times were statistically signiﬁcantly
shorter than those of the NC (P = 0.01) and diabetes
no retinopathy (P = 0.04) groups. No other pairwise
differences were observed.
Intragroup Analysis
Repeated measures analysis of variance, using
a general linear model approach with age, sex, and
iris color as covariates, demonstrated no signiﬁcant
differences between repeat PSRT measures for all
subjects combined and for individual study groups
(Combined: P = 0.86; NC: P = 0.51; diabetes no
retinopathy: P = 0.74; DR: P = 0.20—Greenhouse–
Geisser correction for sphericity violation applied to
all), which suggests the absence of a signiﬁcant learning or fatigue effect, despite the gradual shortening of
successive PSRT measures for each study group.

T2
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Characteristic
Sex (%)
Male
Female
Age (Mean ± SD, years)
Iris Color (%)
Blue
Brown
Hazel
Green
Diabetes Type (%)
Type 1
Type 2
Diabetes Medication (%)
Insulin
Oral HypoG
Combined
None
Diabetes Duration (Mean ± SD,
years)
Visual Acuity

NC (N = 40)

Diabetes
Nonproliferative
Statistical
Diabetes No
Retinopathy (N = 98) Retinopathy (N = 53) Signiﬁcance (ANOVA), P

45
55
56 ± 10

51
49
56 ± 16

62
38
49 ± 10

0.23

43
15
25
17

56
16
14
14

53
19
11
19

0.34

0
0

DM = 20
DM = 80

55
45

,0.01

0
0
0
100
0

20
64
11
5
7.48 ± 6.62

47
40
13
0
15.63 ± 9.56

,0.01

−0.06 ± 0.10

−0.04 ± 0.10

−0.06 ± 0.12

0.70

,0.01

,0.01

ANOVA, analysis of variance; Oral HypoG, oral hypoglycemics; SD, standard deviation.
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F1

F2

Pearson’s correlation revealed a moderate-to-strong
and statistically signiﬁcant relationship between the 3
PSRT measures in the study eye, for all subjects combined (r = 0.44–0.70, P , 0.01 for all; Figure 1) and
for grouped comparisons (r = 0.39–0.71, P = 0.01–
0.04). Paired samples t-tests revealed no PSRT differences between the study and fellow eye for any subgroup (P . 0.05 for all).
Bland–Altman analysis and plots were used to assess
the agreement between successive PSRT measures in
the study eye. The difference in mean recovery time
between PSRT 2 and 3 in the study eye for all subjects
(0.34 seconds), and limits of agreement are presented in
Figure 2. The coefﬁcient of repeatability for all subjects
was 4.01 seconds, and for 59% of the subjects, the
difference in recovery time between PSRT 2 and PSRT
3 was #1 second (#2 seconds for 80% of the subjects),
indicating good within-eye repeatability. The difference
in mean recovery time and coefﬁcient of repeatability,
calculated for individual study groups, closely aligns

to the overall ﬁgures (mean differences range, 0.2–
0.6 seconds; coefﬁcient of repeatability range, 3.92–
4.12 seconds). When comparing PSRT 1 with PSRT
3, the mean difference between recovery time measures
is signiﬁcantly larger (range, 2.4–3.4 seconds across
study groups) and the coefﬁcient of repeatability is signiﬁcantly poorer for the overall group at 6.29 seconds,
and across individual study groups. In addition, differences between recorded recovery times were #1 second
for only 38% of the subjects, indicating poorer repeatability when using the initial PSRT 1 as the baseline
value.
Relationship Between Photostress Recovery Time
and Other Variables
Independent samples t-tests revealed no signiﬁcant
effect of gender (P = 0.26–0.96 across study groups),
iris color (P = 0.06–0.98 across study groups), or diabetes type (P = 0.05–0.36 across study groups) on any

Table 2. Mean PSRT For the First (PSRT 1), Second (PSRT 2), and Third (PSRT 3) Measurements in the Study Eye Across
Study Groups

PSRT 1
PSRT 2
PSRT 3

NCs
Mean ± SD (s)

Diabetes No Retinopathy
Mean ± SD (s)

Diabetes Nonproliferative
Retinopathy
Mean ± SD (s)

Statistical
Signiﬁcance (ANOVA)
P

9.94 ± 3.56
7.63 ± 2.85
7.03 ± 2.41

8.98 ± 3.52
7.16 ± 2.84
6.77 ± 2.91

8.33 ± 3.27
6.04 ± 1.44
5.90 ± 2.36

0.13
0.01
0.09

ANOVA, analysis of variance; s, seconds; SD, standard deviation.
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Fig. 1. Scatterplot demonstrating a strong and statistically
signiﬁcant correlation between
PSRT 2 and PSRT 3 measures
for all subjects.

Fig. 2. Bland–Altman plot
showing mean difference and
95% limits of agreement (0.34 ±
4.01 seconds) for repeat measurements in the study eye (PSRT
2 and PSRT 3) for the overall
subject group.
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of the 3 PSRT measures. Pearson’s correlation, controlling for age and diabetes duration, revealed no signiﬁcant relationship between PSRT and visual acuity
overall (r = −0.05, P = 0.54) and across study groups
(r = −0.03–0.09, P = 0.41–0.90). A statistically significant relationship was found, however, between PSRT
and age overall, Figure 3 (r = 0.15–0.25, P = 0.001–
0.04), and for the NC subgroup for all 3 PSRT measures (r = 0.37–0.45, P = 0.003–0.04). For diabetes
subgroups, however, the relationship with age was
not statistically signiﬁcant (P . 0.05), other than for
PSRT 1 measure in the DR subgroup (r = 0.34, P =
0.02).

Discussion
Photostress recovery devices including the Scotometer,34 the Brightness Acuity Test,35 and the Eger
Macular Stressometer,36 have been developed for the
assessment of ocular health but none have translated
into routine clinical practice. More traditional devices
including the ophthalmoscope and automated perimeter have also been adapted to provide PSRT measures,37,38 but as of yet no device or technique has
provided a universally acceptable and repeatable
PSRT test that is capable of detecting disease presence
or monitoring progression.

Fig. 3. Scatterplot demonstrating the relationship between age
and PSRT 3 for the overall
subject group.

It has previously been shown that PSRT is adversely
affected by conditions affecting the macula, including
central serous retinopathy,39 age-related macular
degeneration,25 and diabetic maculopathy.25–27 Disruption of the retinal pigment epithelium–retina relationship, because of serous retinal detachment or
macular edema for example, has been shown to be
an important factor in the prolongation of PSRT in
such macular disease.40 Importantly, PSRT deﬁcits
have been observed in asymptomatic subjects where
visual acuity is relatively preserved, indicating that
a suitably designed test might provide an effective
indicator of early disease or disease progression.41
This study is the ﬁrst to explore the effect of
diabetes including nonproliferative DR, on PSRT in
comparison to NCs, and to evaluate the repeatability of
PSRT measures among naive subjects with and
without nonproliferative DR. The trend toward shorter
PSRT measures on repeat testing is in general
agreement with previous observations among younger
participants, although the trends were not statistically
signiﬁcant in this study.30 Similar trends have been
observed for other devices, such as the Eger Macular
Stressometer, which was shown to provide repeatable
results and a subtle shortening of PSRT on repeat
testing.36 The general recommendation, however, that
a single practice measure is sufﬁcient to overcome any
possible learning effect, and thereby facilitates a valid
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baseline PSRT measure would seem applicable across
both younger and older populations with and without
nonproliferative DR.
It is interesting to note the shorter PSRT measures
obtained in both diabetic subgroups, in particular the
DR group, when compared with NCs for all three
PSRT measures in the study eye. These differences
were largely nonsigniﬁcant from a statistical perspective, and certainly insigniﬁcant from a clinical perspective. The observed differences most likely reﬂect
the age differences observed between the study
groups, given that the DR group was statistically
younger than the other two groups, and that the NC
subgroup exhibited a positive and signiﬁcant association between PSRT and age. The age differences
observed in the NC subgroup, and for the overall study
sample, are in general agreement with previous
observations on the relationship between PSRT measures and age.34,41,42 In addition, the mean PSRT of the
NC group observed herein (7.03 ± 2.41 seconds for
PSRT 3) is longer than that previously observed in
a younger (mean age, 35 years) normal cohort using
the same device (5.11 ± 1.51 seconds for PSRT 3).30
In the absence of any age-deﬁned normative values for
the device, such age dependency is of clinical relevance and suggests that eye health practitioners should
interpret individual PSRT measures with caution,
except where evidence exists of intereye asymmetry
or elongation of PSRT over time on repeated measures. Of note, PSRT was also measured in the fellow
eye in this study where eligible and no intereye differences were observed for any PSRT measure, which
could prove diagnostic for unilateral disease.
These ﬁndings suggest that neither the diabetes
condition itself nor the presence of nonproliferative
DR as a consequence has an adverse effect on PSRT as
measured using this ﬂash recovery device. The device
would not, therefore, seem capable of detecting the
presence of diabetes or nonproliferative DR, or distinguishing such eyes as distinct from those of normal
persons without diabetes. These ﬁndings are somewhat
in agreement with previous observations of the impact
of early DR on macular recovery dynamics made using
alternate methods. The recovery times among subjects
with background DR were comparable with those
observed among NCs using a macular photostress
test,43 whereas the Eger Macular Stressometer proved
similarly incapable of detecting functional losses associated with DR and other ocular diseases.36 Macular
recovery measured using nyctometry has, however,
been shown to be impaired in early DR.26,27
The presence of diabetic maculopathy, however, has
previously been shown to elongate PSRT measures
and also to cause a prolongation of PSRT on 5-minute

7

repeat testing. Among subjects with diabetic macular
edema, PSRT measures using the same MDD-2 device
averaged in excess of 20 seconds, more than 3 times
the average measures obtained here, for diabetic
subjects without maculopathy.25 These allied ﬁndings
suggest that the ﬂash recovery device is sensitive to
macular changes, and furthermore, that photostress
losses in patients with diabetes are particular to the
development of diabetic maculopathy, the most common cause of visual impairment. This is an important
ﬁnding given that the instrument design is not intuitively suited to the isolation of macular function and
recovery dynamics (the ﬂash area [38°] and stimulus
size [23°] extend signiﬁcantly beyond the central macular area).
The ﬁndings of this study suggest that the MDD-2
may not be sensitive to diabetes, although the device
provides repeatable PSRT measures among normal
and diabetic subjects, with or without nonproliferative
DR. As such, the value of the device would seem
limited to the transition to more advanced diabetic or
other forms of maculopathy, and therefore it is not of
tremendous value as a DR screening tool. Further
research is required to determine whether the device is
a useful tool for longitudinal assessment of macular
function in diabetes and other ocular diseases that
present a risk to macular integrity, and whether it is
useful as an outcome measure in evaluating therapeutic interventions.
Key words: photostress recovery, diabetic retinopathy, maculopathy, repeatability, MDD-2.
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